Table 5

Canonical pathway analysis of the constructed interaction networks in primary and metastatic prostate cancer
Canonical pathway analysis p-value (<0.05)
Primary prostate cancer
Pathways in cancer 1.70e-03
Rb1 pathway 5.95e-03
Retinoic acid pathway 6.61e-03
Aurora A pathway 7.44e-03
Beta-catenin degradation pathway 9.95e-03
Wnt/beta-catenin pathway 1.03e-02
Wnt canonical signaling pathway 1.34e-02
Met pathway (signaling of HGF receptor) 1.39e-02
P38-alpha/beta downstream pathway 1.52e-02
Beta-catenin nuclear pathway 1.58e-02
Aurora B pathway 1.66e-02
EPHB forward pathway 1.81e-02
IFN-gamma pathway 1.81e-02
P53 hypoxia pathway 1.97e-02
MYC repress pathway 2.15e-02
Progesterone mediated oocyte maturation 2.19e-02
Rac CycD pathway (Ras and Rho protein on G1/S transition) 2.73e-02
PLK1 pathway 2.88e-02
IL-6 (interleukin-6) pathway 3.08e-02
FGFR2C ligand binding and activation 3.58e-02
Cell cycle 4.43e-02
PDGFR-beta signaling pathway 4.59e-02
Metastatic prostate cancer
MYC activate pathway 1.41e-04
ErbB network pathway 2.78e-03
KIT receptor signaling pathway 3.28e-03
IL-10 pathway 4.40e-03
Pathways in cancer 4.76e-03
ErbB4 pathway 6.12e-03
Her2 pathway (ErbB2 in signal transduction and oncology) 8.51e-03
Yap1 and Wwtr1/Taz stimulated gene expression 1.09e-02
Smooth Muscle Contraction 1.22e-02
Barrestin pathway 1.53e-02
IL-6 signaling pathway 1.85e-02
STAT3 pathway 1.85e-02
IL-2/STAT5 pathway 2.00e-02
RAS pathway 2.00e-02
ErbB2/ErbB3 signaling pathway 2.19e-02
Syndecan4 pathway 2.38e-02
PPAR-alpha pathway 2.61e-02
Integrin signaling pathway 3.72e-02
Rela pathway 3.78e-02
HDAC class I pathway 3.94e-02
FOXM1 pathway 4.24e-02
IL-7 pathway 4.23e-02
EGFR pathway 4.70e-02

Kim et al.

Kim et al. BMC Systems Biology 2013 7:47   doi:10.1186/1752-0509-7-47

Open Data